Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study
Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. The latest results from the trial were recently discussed at the 2018 Annual European Congress of Rheumatology (EULAR) held in Amsterdam,…